Nurix Therapeutics (NRIX) Accounts Payables (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Accounts Payables data on file, last reported at $10.3 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $10.3 million, up 22.58% year-over-year; the trailing twelve-month figure through Feb 2026 was $10.3 million (up 22.58% YoY), and the FY2025 annual result was $11.2 million, down 2.33% from the prior year.
• Accounts Payables retreated to $10.3 million in Q1 2026 per NRIX's latest filing, from $11.2 million in the prior quarter.
• Over five years, Accounts Payables peaked at $11.5 million in Q4 2024 and troughed at $2.2 million in Q3 2023.
• A 5-year average of $6.5 million and a median of $6.0 million in 2022 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables tumbled 63.87% in 2023, then jumped 119.73% in 2025.
• A 5-year view of Accounts Payables shows it stood at $5.1 million in 2022, then advanced by 26.4% to $6.4 million in 2023, then surged by 79.38% to $11.5 million in 2024, then dropped by 2.33% to $11.2 million in 2025, then declined by 8.22% to $10.3 million in 2026.
• Business Quant data shows NRIX's Accounts Payables at $10.3 million in Q1 2026, $11.2 million in Q4 2025, and $8.6 million in Q3 2025.